@lizparry's tirzepatide claims, fact-checked

What did @lizparry actually say?

She walked through reconstituting what she calls "trisaptide" (tirzepatide) purchased from an unregulated peptide vendor. The core claim is straightforward: she dissolved 10 mg of powder in 100 units of bacteriostatic water, calculated that every 25 units drawn equals 2.5 mg, and called that a "microdose" appropriate for PCOS and inflammation management. She sourced her protocol not from a clinician but from a nurses' Reddit thread.

She also named a specific vendor, tides.ist, and mentioned she ordered from a second "USA-based" site. She is not claiming a cure. She is sharing a personal regimen and telling viewers to "do your research." That framing matters for context, but it does not reduce the risk of 134,000 people watching someone self-inject an unregulated peptide based on Reddit math.

Does the science back this up?

The reconstitution math is arithmetically correct, but that is the least important part of this picture. Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro and Zepbound. The clinical evidence for it is real and substantial. What is not real is any clinical evidence for tirzepatide sourced from unregulated peptide vendors.

Frías et al. (2021, New England Journal of Medicine) established tirzepatide's efficacy profile in the SURPASS trials at doses starting at 5 mg weekly, not 2.5 mg. A 2.5 mg weekly starting dose was later studied in the SURMOUNT-5 trial design and in some compounding protocols, so the dose is not fantasy. However, Drucker (2022, Cell Metabolism) and others have repeatedly noted that peptide vendor products carry no purity guarantees, no sterility verification, and no regulatory oversight. The gap between "the molecule works" and "this powder from tides.ist is that molecule" is enormous and cannot be bridged by Reddit consensus.

On PCOS specifically, there is emerging but preliminary evidence. Cree-Green et al. and other researchers have explored GLP-1 receptor agonists for insulin resistance in PCOS, but no large randomized controlled trials exist yet for tirzepatide specifically in PCOS populations.

What did they get wrong (or right)?

The math is right. Twenty-five units out of 100 units of bacteriostatic water mixed with 10 mg does equal 2.5 mg per pull. Give credit where it is due: she did not make a calculation error, which is more than can be said for a lot of peptide content online.

What she got wrong is more serious. Calling 2.5 mg a "microdose" is imprecise. In the clinical literature, microdosing typically refers to sub-pharmacological doses well below the therapeutic threshold. A 2.5 mg weekly dose of tirzepatide is an actual starting dose, as commenters in her own video apparently told her. She acknowledges this but dismisses it without resolution. More importantly, sourcing injectable peptides from an unverified vendor and self-administering based on a Reddit thread carries risks she does not address: contamination, endotoxins, incorrect concentration labeling, and no medical supervision for side effects like pancreatitis, tachycardia, or severe GI events. The phrase "do your research" does not constitute a safety framework.

What should you actually know?

If you have PCOS and you are interested in GLP-1 or dual GIP/GLP-1 receptor agonists, that interest is medically reasonable. The science on insulin sensitization in PCOS is genuinely evolving. But the path from "this class of drugs is promising" to "I will inject unverified powder I bought online" skips several steps that exist for reasons.

FDA-approved tirzepatide (Mounjaro, Zepbound) is available through licensed prescribers and in some cases through regulated telehealth. Compounded tirzepatide from 503B outsourcing facilities operates in a different regulatory category from peptide vendor products and should not be treated as equivalent. The FDA has issued warnings specifically about compounded semaglutide and tirzepatide products from unregistered facilities. Vendor peptides sold as "research chemicals" carry no such oversight at all.

• A qualified clinician can assess whether a GLP-1 agent is appropriate for your specific PCOS presentation.
• If cost is the barrier, that is a real and legitimate problem, but it does not make unregulated injectable sourcing safe.
• Bacteriostatic water reconstitution technique, storage, and injection site hygiene matter and are not covered in a 60-second TikTok.